BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:00 PM
 | 
Feb 28, 2007
 |  BC Extra  |  Top Story

Amgen receives SEC inquiry

AMGN said in a regulatory filing on Wednesday that it received an informal inquiry from the SEC's Atlanta District Office requesting information and documentation related to the independently done DAHANCA10 study. Interim data from the study showed that Aranesp plus radiation missed the primary endpoint of 3-year loco-regional control vs. radiation alone. The trial was stopped in December 2006....

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >